5 Quick Questions with PK Dutta

P.K. DUTTA, Ph.D., SVP Sales Nanologica AB

Who are you?

I am a Molecular Biologist by training. I have spent most of my career dealing with large scale silica based industrial purification of peptides and small molecules. Before joining Nanologica, I held leadership and strategic roles for global silica brands like Waters, Kromasil and YMC. I am very honored to be part of the Nanologica Business Development Team, establishing a more significant presence in the US, where I am also based.


What is your current focus?

My focus is to introduce Nanologica’s silica for preparative chromatography to several prep HPLC customers in the US.


What is your view on the development of the prep market in the US?

The peptide-based drug discovery market continues to grow at a rapid pace.  Industrial reversed-phase HPLC will always remain an essential component for synthetic peptide manufacturing. Another exciting aspect is the recent approval of more GLP-1 analogues for the treatment of obesity. As GLP-1 analogues require prep HPLC for purification, this may open the doors to another huge market in the US and globally.


What do you look forward to?

I am looking forward to hearing from customers about their experiences with our silica on better loadability, selectivity, mechanical and chemical stability, and lifetime for their peptide purification. Thanks to our proprietary manufacturing process of the silica, I firmly believe we can improve those parameters for the benefit of our customers.


How does this contribute to Nanologica’s vision of better and cheaper medicine through porous silica?

Nanologica’s industrial-scale cGMP silica production offers untapped growth potential. Given the silica’s exceptional mechanical and chemical stability, it is an excellent choice for customers manufacturing peptides such as insulin, insulin and GLP analogues and small molecules. Our silica can improve productivity and reduce manufacturing costs for our customers. Nanologica’s silica could lead to more cost-effective treatments for patients worldwide, and more patients could then afford the drugs they need.


5 Quick Questions with PK Dutta

Share this: